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In order to get insight into the density of blood vessels in the stroma of benign and malignant trichogenic neoplasms,
immunohistological quantification of CD 31 positive vessels was performed in 112 tumors, comprised of 50 BCCs of nodular
(35) or morphoeic (15) growth patterns, 17 Pinkus’ tumors, as well as 17 trichoepitheliomas of which 6 were desmoplastic, 8
trichofolliculomas, and 20 trichoblastomas. Methods. Vessel density was counted within the tumors, in the tumor-surrounding
stroma, and, as a control, in the normal skin of the operation specimen. The results were compared using statistical methods.
Results. Whereas, irrespective of the patients’ age and location of tumors, the vessel density in normal skin showed no significant
differences (8.8 ± 2.7), the counts in the peritumoral stroma revealed significant differences between the different tumors
investigated. The highest counts were obtained in BCC (24.7 ± 6.7) and the lowest in benign trichogenic neoplasms (around
14) Pinkus’ tumors revealed intermediate counts (19.7 ± 6.6). The vessel densities within the tumors were generally low, and no
correlation to the dignity was found. Conclusion. Determination of blood vessel density in the peritumoral stroma may be an
additional parameter for differential diagnosis of trichogenic tumors of uncertain dignity.
1. Introduction
The skin receives its blood supply via a deep dermal plexus
and a superficial, subpapillar plexus. Growth of dermal
vasculature mainly occurs during embryogenesis and is
regulated—as detected since the 1980s—by a variety of
soluble factors of angiogenesis and antiangiogenesis [1].
VEGF is known as the main proangiogenic factor, and
important antiangiogenic factors are thrombospondin 1 and
2. The vessel shape and number stay constant as long as
a balance of pro and antiangiogenic stimuli exists [2]. In
1971, Folkman proposed that tumor growth is dependent
on angiogenesis [3]. Angiogenesis is also important in a
variety of other diseases, with hypoxia and inflammation
as known stimuli [4, 5]. Without angiogenesis, a tumor
does not reach a size larger than 1-2mm and also will
not metastasise [6]. The so-called angiogenic switch is
characterized by predomination of proangiogenic factors,
followed by formation of new vessels [7, 8]. Higher levels
of microvessel densities, as measured in histologic specimen,
were found associated with adverse prognosis in a variety of
tumor entities [9–13].
The aim of this study was the question as to whether
microvessel density may be associated with the biological
behaviour of trichogenic tumors arising in human skin, and,
therefore, their immunohistological determination might
facilitate differential diagnosis between BCCs and their
histological simulators.
2. Material and Methods
The 112 tumors derived from the dermatopathologic
archives of the institution. Tumors had been excised from
2000 to 2008. Data on diagnosis, on age and sex of patients
and location of the lesions as well as normal skin of the exci-
sion specimen were available (Tables 1 and 2). The tumors
chosen for study were 50 basal cell carcinomas (BCCs),
of which were 35 nodular BCCs and 15 morphoeic BCCs;
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Table 1: Age and sex distribution.
Tumor Mean age± SD Range Male Female
Nodular BCCs (n = 35) 75,1 ± 12,1 46–97 20 (57,1%) 15 (42,9%)
Morphoeic BCCs (n = 15) 76,1 ± 9,5 56–93 11 (73,3%) 4 (26,7%)
Pinkus’ tumor (n = 17) 60,6 ± 13,6 32–80 5 (29,4%) 12 (70,6%)
Trichoblastoma (n = 20) 57,0 ± 18,0 21–91 15 (75,0%) 5 (25,0%)
Trichofolliculoma (n = 8) 56,4 ± 20,2 23–86 1 (12,5%) 7 (87,5%)
Trichoepithelioma (n = 11) 46,7 ± 17,7 25–79 3 (27,3%) 8 (72,7%)
Desmoplastic Trichoepithelioma (n = 6) 47,2 ± 17,4 18–64 1 (16,7%) 5 (83,3%)
Table 2: Location of tumors.
Location Nod
BCCs
Morph
BCCs
P TB TF TE DTE
Capillitium 1 9 2 1
Face
Cheek 6 3 3 1 3
Forehead 4 3 2 1 1 1
Chin 1
Temple 5 2 1
Nose 8 5 1 2 5
Ear 1
Retroauricular 1
Chest and back 2 1 8 4 1
Neck 4
Shoulder 1 1 1 1 1
Abdomen 4
Limbs 3 1 4 2
Total 35 15 17 20 8 11 6
Nod BCCs: nodular basal cell carcinoma. Morph BCCs: morphoeic basal
cell carcinoma. P: Pinkus’ tumor. TB: trichoblastoma. TF: trichofollicu-
loma. TE: trichoepithelioma. DTE: desmoplastic trichoepithelioma.
17 Pinkus’ tumors, 17 trichoepitheliomas of which 6 were
of desmoplastic growth pattern, 8 trichofolliculomas, and 20
trichoblastomas (Table 2).
The specimens were formalin-fixed and paraffin embed-
ded. Serial sections were stained with H&E and CD31
(Clone JC70A, Dako Denmark, dilution 1 : 30) following
routine immunohistological methods using Aethylcarbazole
as chromogen and hematoxyline as counterstain. Counting
of CD31 positive vessel structures was performed with a
200-time magnification using a squaric grid. Counting in
at least six and at most 10 fields was done separately in
the normal skin of the excision tips, in the peritumoral
stroma, and within the tumors. Statistical evaluation was
performed using the program statistical package for social
sciences, version 15.0.1 (SPSS). Boxplots were performed
for the graphics. The values for peritumoral vessel densities
underwent a single factorial variance analysis followed by
a post-hoc test (Tukey-HSD). P ≤ .05 was chosen as level
of significance. Clinical data were evaluated using Microsoft
Office Excel 2003.
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Figure 1: Boxplot for themicrovessel counts in peritumoral stroma,
tumor, and normal skin.
3. Results
3.1. Low Variation of Vessel Density in Normal Skin. Irrespec-
tive of the diagnosis, the location of lesions, and age/sex of
patients, the vessel densities in the uninvolved skin of the
operation specimen were rather low (8.8 ± 2.7) and did not
vary significantly (Figures 1 and 2).
3.2. Low Intratumoral Vessel Density. The vessel density
within the tumor tissue was surprisingly low—even lower
than in normal skin—with mean values of 3.1 ± 2.9,
irrespective of tumors dignity (Figures 1 and 2).
3.3. High Vessel Density in the Peritumoral Stroma of Malig-
nant Tumors. In contrast to the generally low intratumoral
vessel densities the number of CD 31 positive vessels in
the tumor-surrounding stroma was higher (Figure 1), and
showed a significant correlation to the tumors’ dignity
(Figure 2): Whereas nodular BCCs revealed 24.7 ± 6.7
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Figure 2: Boxplot for the microvessel counts in the tumor entities
and tissue types.
peritumoral vessels/field the count for trichoblastomas—
their benign counterparts—was 15.3 ± 5.1. This difference
was highly significant (P < .0001). A CD 31-stained section
of a nodular BCCs shows many vessels (Figure 3(a)) and
CD 31 stained section of a trichoblastoma only a few vessels
(Figure 3(b)). The Pinkus’ tumors revealed intermediate
counts (19.7 ± 6.6). Microvessel density in a CD 31 stained
section of a Pinkus’ tumor is on an intermediate level
(Figure 3(c)). The mean counts and variations obtained in
the different tumor entities are listed in Figure 2. Statistically
significant differences were neither obtained between the
different BCCs (nodular versus morphoeic) nor between all
benign trichogenic tumors investigated.
4. Discussion
Angiogenesis is essential for tumor growth. This was already
postulated by Rudolf Virchow in 1863 [14], and by Folkman
in 1971 [3]. In a variety of human cancers, blood vessel
density was found correlated to tumor aggressiveness and
prognosis [15–18]. Angiogenesis and tumor vasculature
serve as targets for innovative oncologic therapy regimen
[19]. The aim of the study presented here was to evalu-
ate whether blood vessel density as the result of former
angiogenesis might reflect the biologic behaviour (dignity)
of BCCs and benign cutaneous tumors derived from hair
follicles. For this purpose, a rather large series of 112 benign
and malignant trichogenic skin neoplasms was studied with
regard to small blood vessel density in the tumor stroma.
Noninvolved skin of the operation specimen served as
control. The method used here well has limitations because
(a)
(b)
(c)
Figure 3: (a) CD 31 stained section of a nodular BCCs shows many
vessels (200x magnification). (b) In a CD 31-stained section of a
trichoblastoma, only a few vessels can be seen (200x magnification).
(c) Microvessel density in a CD 31 stained section of a Pinkus’
tumor is on an intermediate level (200x magnification).
wavy vessels may be cut several times. To exactly follow
one and the same vessel in a given tumor, other methods
are required. However, the aim of our study was to answer
the question whether the assessment of tumor-associated
blood vessel density with the means of a “routine” method
applicable by dermatopathologists might be helpful to
discriminate different types of BCCs from their histological
simulators.
In contrast to normal skin, significant variations of
blood vessel densities were found in the peritumoral stroma
of different tumor entities, where the highest counts were
present in BCCs and significantly lower counts in the
4 Journal of Skin Cancer
peritumoral stroma of benign tumors such as trichofol-
liculomas, trichoepitheliomas, and trichoblastomas. The
latter two may lead to differential diagnostic difficulties: in
particular, desmoplastic trichoepithelioma may be confused
with morphoeic BCCs and trichoblastoma with nodular
BCCs. Our results show that determination of peritumoral
microvessels might serve as an aid for differential diagnosis.
VEGF, the main proangiogenetic cytokine, has been found
increased in BCCs compared to normal skin, although to
a lesser extent than in cutaneous squamous cell carcinoma
(SCC) [20]. VEGF in BCCs was shown to be correlated to
blood vessel density [21]. Our data showing a strikingly low
intratumoral vessel density in all tumors investigated are
in line with earlier reports comparing BCCs and SCC [10–
12]. What means the paucity of small blood vessels within
the epithelium of nodular BCCs compared to the plethora
of those in the peritumoral stroma biologically? Some
authors attribute intratumoral vessel formation to metastatic
capacity of SCC in contrast to BCCs [12]. The peritumoral
vessel density in BCCs was attributed to local aggressiveness
[13, 22]. The focus of this study was the comparison between
BCCs and their benign counterparts rather than compar-
ison of variable vessel densities of more or less aggressive
BCCs. Interestingly, the fibroepithelioma Pinkus displayed
intermediate numbers of peritumoral vessels as compared
to BCCs and compared to truly benign trichogenic neo-
plasms showing their “intermediate malignancy”. Are BCCs-
associated blood vessels affected by the known pathogenic
pathway of BCCs, the smoothened/Gli pathway activated due
to absence/reduction of PTCH signalling? Translocations or
mutations that are characteristic of distinct tumors have been
detected in stromal cells as well [23]. A recent observation
might disprove this in BCCs, since we observed in BCCs
regressed during oral treatment with an inhibitor of the
smo/gli pathway that in absence of tumor cells, the vessel-
containing tumor bed was still present (data not shown).
The question as to whether stromal fibroblasts in BCCs carry
the PTCH mutation is, to our knowledge, not answered
yet.
A number of studies have been performed to evaluate
ancillary diagnostic tools that might differentiate BCCs
from benign trichoblastic neoplasms. Immunohistochemical
approaches to differentiate between these entities included
the expression of androgen receptor, CD34, bcl-2, TGF-
[beta], CD10, and staining for tumor-associatedMerkel cells.
Androgen receptor expression was detected in about 80% of
basal cell carcinomas. Different from basal cell carcinomas,
benign trichoblastic neoplasms showed no expression of
androgen receptor [24]. CD34 was shown to be strongly
expressed in the tumor-associated stroma of trichoepithe-
lioma and absent or only focal in the dermis surrounding
the nests of BCCs [25]. Bcl-2 expression was found diffuse in
BCCs andmostly patchy and peripheral in trichoepithelioma
[26]. TGF-[beta] staining is positive in trichoepithelioma
and negative in most BCCs [27]. CD10 was postulated as
useful for distinguishing between BCCs with widespread
follicular differentiation and trichoblastomas [28]. Merkel
cells are absent in most BBC and preferentially detectable
in trichoepithelioma and trichoblastoma [29]. Cytokeratins
have not been helpful, as their expression and staining
pattern are generally similar in benign trichoblastic tumors
and BCCs [29].
In conclusion, the data obtained in a large series
of benign and malignant trichogenic tumors show that
determination of peritumoral small vessel density by CD31
immunohistology adds reliable information to histological
differential diagnosis.
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